Call us
+44 (0) 161 359 5813
Pharmaceuticals and Healthcare

PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024

Report code: GDHC117PIDR
Publisher: GlobalData Healthcare
  • Adobe PDF
  • Microsoft Excel
Published: Jan-2016
Number of pages: 268
Key Benefits
  • Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.

    Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.

    For the purposes of this report, GlobalData defines the HBV infection therapeutics market to include sales of HBV-specific medication in patients 18 years and older in the eight major pharmaceutical markets (8MM; US, France, Germany, Italy, Spain, UK, Japan, and China). GlobalData expects the market to experience moderate growth that will be primarily driven by the uptake of therapies with novel mechanisms of action (MOAs).


    Overview of chronic HBV infection, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

    Topline HBV therapeutics market revenue from 2014–2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

    Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the HBV therapeutics market.

    Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

    Analysis of the current and future market competition in the global HBV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

  • Request Sample Pages

    captcha refresh

Special Offer

Expires 11 November 2016

30% off
  • ?
    Electronic PDF copy delivered via email.

    Report can be used by individual purchaser only.

    $10995 $7697
  • ?
    Electronic PDF copy delivered via email.

    Report can be shared by unlimited users within one corporate location,
    e.g. a regional office.

    $21990 $15393
  • ?
    Electronic PDF copy delivered via email.

    Report can be shared globally by unlimited users within the purchasing corporation
    e.g. all employees of a single company.

    $32985 $23090
Add to cart

Talk to us

Call us on +44 (0) 161 359 5813

Research Support

Get one-to-one support from our expert analysts only when you buy direct

Price Guarantee

You will not find our reports cheaper anywhere else

Customer Focused

Our client support team are on-hand to assist with your research needs

Unrivalled Expertise

700+ analysts delivering actionable insight